BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Abiraterone (Primary) ; Olaparib (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Aug 2017 According to a Tempus media release, this study will screen 400 patients across over 20 participating centers.
- 17 Aug 2017 According to a Tempus media release, Tempus will be responsible for the sequencing and analytics for this study.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.